Bellevue Group Ag Kezar Life Sciences, Inc. Transaction History

Bellevue Group Ag

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$3.13 - $7.31 $9.46 Million - $22.1 Million	-3,021,000 Reduced 99.67%	10,000 $31,000
Q3 2022 Nov 14, 2022	SELL	$7.99 - $10.75 $31,960 - $43,000	-4,000 Reduced 0.13%	3,031,000 $26.1 Million
Q2 2022 Aug 11, 2022	SELL	$4.58 - $17.13 $7.48 Million - $28 Million	-1,633,148 Reduced 34.98%	3,035,000 $25.1 Million
Q1 2022 May 13, 2022	SELL	$12.3 - $18.33 $3.08 Million - $4.58 Million	-250,000 Reduced 5.08%	4,668,148 $77.6 Million
Q4 2021 Feb 10, 2022	BUY	$7.44 - $16.72 $2.86 Million - $6.44 Million	385,000 Added 8.49%	4,918,148 $82.2 Million
Q3 2020 Nov 16, 2020	BUY	$4.36 - $5.5 $1.27 Million - $1.6 Million	291,208 Added 6.86%	4,533,148 $21.9 Million
Q2 2020 Aug 13, 2020	BUY	$3.6 - $7.75 $2.6 Million - $5.6 Million	723,051 Added 20.55%	4,241,940 $22 Million
Q1 2020 May 14, 2020	BUY	$2.77 - $5.75 $5.45 Million - $11.3 Million	1,968,220 Added 126.93%	3,518,889 $15.3 Million
Q4 2019 Feb 14, 2020	BUY	$2.5 - $4.26 $800,365 - $1.36 Million	320,146 Added 26.02%	1,550,669 $6.22 Million
Q2 2019 Aug 14, 2019	BUY	$7.09 - $21.9 $8.72 Million - $26.9 Million	1,230,523 New	1,230,523 $9.49 Million

38.4M

13.8K

600

Ticker KZR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,369,504
Market Cap $446M
Description
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical tria...

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

Stay updated on Bellevue Group Ag with notifications on news.